Terms: = Ovarian cancer AND ACVR2A, ACVR2, 92, ENSG00000121989, ACTRII, P27037 AND Clinical Outcome
26 results:
1. clinical Relevance of Mortalin in ovarian cancer Patients.
Rajtak A; Czerwonka A; Pitter M; Kotarski J; Okła K
Cells; 2023 Feb; 12(5):. PubMed ID: 36899836
[No Abstract] [Full Text] [Related]
2. Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial.
Capoluongo ED; Pellegrino B; Arenare L; Califano D; Scambia G; Beltrame L; Serra V; Scaglione GL; Spina A; Cecere SC; De Cecio R; Normanno N; Colombo N; Lorusso D; Russo D; Nardelli C; D'Incalci M; Llop-Guevara A; Pisano C; Baldassarre G; Mezzanzanica D; Artioli G; Setaro M; Tasca G; Roma C; Campanini N; Cinieri S; Sergi A; Musolino A; Perrone F; Chiodini P; Marchini S; Pignata S
ESMO Open; 2022 Oct; 7(5):100585. PubMed ID: 36156447
[TBL] [Abstract] [Full Text] [Related]
3. clinical outcome of pulmonary lymphangitic carcinomatosis in gynecologic malignancy: A single-institution experience.
Kim MS; Jeong SY; Lee YY; Choi CH; Kim TJ; Kim BG; Bae DS; Lee JW
Taiwan J Obstet Gynecol; 2022 Mar; 61(2):333-338. PubMed ID: 35361397
[TBL] [Abstract] [Full Text] [Related]
4.
Liontos M; Zografos E; Zoumpourlis P; Andrikopoulou A; Svarna A; Fiste O; Kunadis E; Papatheodoridi AM; Kaparelou M; Koutsoukos K; Thomakos N; Haidopoulos D; Rodolakis A; Dimopoulos MA; Zagouri F
Curr Oncol; 2021 Nov; 28(6):4446-4456. PubMed ID: 34898566
[TBL] [Abstract] [Full Text] [Related]
5. Importance of Enhanced Recovery After Surgery (ERAS) Protocol Compliance for Length of Stay in ovarian cancer Surgery.
Sánchez-Iglesias JL; Gómez-Hidalgo NR; Pérez-Benavente A; Carbonell-Socias M; Manrique-Muñoz S; Serrano MP; Gutiérrez-Barceló P; Bradbury M; Nelson G; Gil-Moreno A
Ann Surg Oncol; 2021 Dec; 28(13):8979-8986. PubMed ID: 34091804
[TBL] [Abstract] [Full Text] [Related]
6. Prognostic role of thrombocytosis in recurrent ovarian cancer: a pooled analysis of the AGO Study Group.
Canzler U; Lück HJ; Neuser P; Sehouli J; Burges A; Harter P; Schmalfeldt B; Aminossadati B; Mahner S; Kommoss S; Wimberger P; Pfisterer J; de Gregorio N; Hasenburg A; Gropp-Meier M; El-Balat A; Jackisch C; du Bois A; Meier W; Wagner U
Arch Gynecol Obstet; 2020 May; 301(5):1267-1274. PubMed ID: 32277253
[TBL] [Abstract] [Full Text] [Related]
7. Molecular profiling identifies synchronous endometrial and ovarian cancers as metastatic endometrial cancer with favorable clinical outcome.
Reijnen C; Küsters-Vandevelde HVN; Ligtenberg MJL; Bulten J; Oosterwegel M; Snijders MPLM; Sweegers S; de Hullu JA; Vos MC; van der Wurff AAM; van Altena AM; Eijkelenboom A; Pijnenborg JMA
Int J Cancer; 2020 Jul; 147(2):478-489. PubMed ID: 32022266
[TBL] [Abstract] [Full Text] [Related]
8. CA-125 reduction during neoadjuvant chemotherapy is associated with success of cytoreductive surgery and outcome of patients with advanced high-grade ovarian cancer.
Kessous R; Wissing MD; Piedimonte S; Abitbol J; Kogan L; Laskov I; Yasmeen A; Salvador S; Lau S; Gotlieb WH
Acta Obstet Gynecol Scand; 2020 Jul; 99(7):933-940. PubMed ID: 31954071
[TBL] [Abstract] [Full Text] [Related]
9. Clinicopathological and molecular characterisation of 'multiple-classifier' endometrial carcinomas.
León-Castillo A; Gilvazquez E; Nout R; Smit VT; McAlpine JN; McConechy M; Kommoss S; Brucker SY; Carlson JW; Epstein E; Rau TT; Soslow RA; Ganesan R; Matias-Guiu X; Oliva E; Harrison BT; Church DN; Gilks CB; Bosse T
J Pathol; 2020 Mar; 250(3):312-322. PubMed ID: 31829447
[TBL] [Abstract] [Full Text] [Related]
10. Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China.
Ni J; Cheng X; Zhou R; Xu X; Guo W; Chen X
J Ovarian Res; 2019 Nov; 12(1):117. PubMed ID: 31775908
[TBL] [Abstract] [Full Text] [Related]
11. The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole.
George A; McLachlan J; Tunariu N; Della Pepa C; Migali C; Gore M; Kaye S; Banerjee S
BMC Cancer; 2017 Jun; 17(1):456. PubMed ID: 28666422
[TBL] [Abstract] [Full Text] [Related]
12. Immunophenotype and human papillomavirus status of serous adenocarcinoma of the uterine cervix.
Togami S; Sasajima Y; Kasamatsu T; Oda-Otomo R; Okada S; Ishikawa M; Ikeda S; Kato T; Tsuda H
Pathol Oncol Res; 2015 Apr; 21(2):487-94. PubMed ID: 25370301
[TBL] [Abstract] [Full Text] [Related]
13. clinical characteristics and outcomes of uterine tumors resembling ovarian sex-cord tumors (UTROSCT): a systematic review of literature.
Blake EA; Sheridan TB; Wang KL; Takiuchi T; Kodama M; Sawada K; Matsuo K
Eur J Obstet Gynecol Reprod Biol; 2014 Oct; 181():163-70. PubMed ID: 25150955
[TBL] [Abstract] [Full Text] [Related]
14. Dualistic classification of epithelial ovarian cancer: surgical and survival outcomes in a large retrospective series.
Panici PB; Marchetti C; Salerno L; Musella A; Vertechy L; Palaia I; Perniola G; Ruscito I; Boni T; Angioli R; Muzii L
Ann Surg Oncol; 2014 Sep; 21(9):3036-41. PubMed ID: 24770721
[TBL] [Abstract] [Full Text] [Related]
15. Prognostic value of HER-2/neu expression in epithelial ovarian cancer: a meta-analysis.
Wang Y; Wang D; Ren M
Tumour Biol; 2014 Jan; 35(1):33-8. PubMed ID: 23873100
[TBL] [Abstract] [Full Text] [Related]
16. Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death.
Nick AM; Stone RL; Armaiz-Pena G; Ozpolat B; Tekedereli I; Graybill WS; Landen CN; Villares G; Vivas-Mejia P; Bottsford-Miller J; Kim HS; Lee JS; Kim SM; Baggerly KA; Ram PT; Deavers MT; Coleman RL; Lopez-Berestein G; Sood AK
J Natl Cancer Inst; 2011 Nov; 103(21):1596-612. PubMed ID: 21957230
[TBL] [Abstract] [Full Text] [Related]
17. [Expression and prognostic significance of EphA2 and EphrinA-1 in ovarian serous carcinomas].
Han LP; Liu JF; Liu XR; Dong ZM; Suo ZH
Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 Mar; 42(2):179-84. PubMed ID: 21500549
[TBL] [Abstract] [Full Text] [Related]
18. A 12-gene genomic instability signature predicts clinical outcomes in multiple cancer types.
Mettu RK; Wan YW; Habermann JK; Ried T; Guo NL
Int J Biol Markers; 2010; 25(4):219-28. PubMed ID: 21161944
[TBL] [Abstract] [Full Text] [Related]
19. Serous and mucinous borderline ovarian tumors: are there real differences between these two entities?
Benito V; Lubrano A; Arencibia O; Medina N; Álvarez Eva E; Andújar M; Falcón Juan M; Falcón O
Eur J Obstet Gynecol Reprod Biol; 2010 Dec; 153(2):188-92. PubMed ID: 20728981
[TBL] [Abstract] [Full Text] [Related]
20. clinical outcome of Iranian patients with advanced ovarian cancer with neoadjuvant chemotherapy versus primary debulking surgery.
Ghaemmaghami F; Karimi-Zarchi M; Modares-Gilani M; Mousavi A; Behtash N
Asian Pac J Cancer Prev; 2008; 9(4):719-24. PubMed ID: 19256766
[TBL] [Abstract] [Full Text] [Related]
[Next]